Open access
Sep 2026
TP53 mutation is associated with selective upregulation of LAG3 independent of immune infiltration and antigen-presentation signatures in WHO grade 4 glioma
Abstract Background Lymphocyte activation gene 3 (LAG3) has emerged as a clinically actionable immune checkpoint target in oncology, but its molecular determinants in glioma remain poorly characterized. We aimed to determine whether TP53 mutation is associated with LAG3 expression, whether this is selective among immun...
Y. Uemae, Shunichiro Miki, E. Yamada et al.
· Neuro-Oncology Advances · 0 citations